---

Background and Objective: Wilson’s disease (WD) is caused by mutation to the cooer-transporting gene ATP7B. Chelation therapy is the main protochol of treatment for patients with Wilson’s disease. D-penicillamine is one of the well-known chelator agants which is used in WD treatment but it can not enter into the intracellular space.This study was done to evaluate the synthesis and anti-intracellular Copper overload evaluation of Nanoconjugated D-penicillamine –Dendrimer in Wilson’s model cells. Methods: In this descriptive-analytic study, initially 0.01 mm polyethylene glycol (PEG) and 0.0018 mm citric acid, Dendrimer was synthesized. After purification by dialysis bag and lyophilization, 10mg dendrimer was conjugated to 3.3mg D-penicillamine. Nanoconjugated D-penicillamine-dendrimer was injected on Wilson’s model cells. After incubation and centrifugation intracellular measurement of copper concentration and FTIR test were done. Results: Copper accumulation significantly reduced in the HepG2 WD cell by Nanoconjugated D-penicillamine - Dendrimer in compared to D-penicillamine (P<0.05). Copper accumulation was determined to be 46.61. MTT assay showed no toxicological damage in HepG2 WD cell. Conclusion: Nanoconjugated D-penicillamine –Dendrimer can reduces intracellular concentration of Copper.

---

Background and Objective: Infantile colic which can cause nervousness and anxiety in parents by fussing and restlessness in babies. This study was done to determine the prevalence and associated risk factors of infantile colic in Babol, the North of IRAN.
Methods: This descriptive-analytical study was done on 591 breastfeeding babies (321 females, 270 males) born with birth weight 2500-4000 grams and gestational age ≥37 weeks without any medical problem during 2016-18. They visited in age 2, 4, 8, 12 weeks by neonatologist. On the basis of parents complain and Wessel's criteria babies were divided into three groups: Cramp with crying (colicky group), Cramp without crying and normal group. Then possible risk factors of infantile colic have been compared in three groups.
Results: 45.5% of babies presented cramp with crying as colic group. Time of restlessness was significantly more than morning during night and afternoon (P<0.05). Colic was higher in infants born by cesarean section (P<0.05), and in the first-born child (P<0.05). However, there was not significant relation with gender, mothers’ education, parents smoking and taking dairy product.
Conclusion: According to this study’s findings, nearly half of infants had the symptoms of colic, which was higher in first children, infants born by cesarean section and during night.

---

Background and Objective: Chronic use of opioids leads to analgesic tolerance. Protein kinase C (PKC), adenylyl cyclase (AC), nitric oxide (NO) and glycogen synthase kinase 3 beta (GSK-3β) are involved in morphine tolerance. Lithium activates the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) pathway that inhibits GSK-3β and reduces morphine-induced tolerance. This study was performed to evaluate the effects of lithium on morphine dependence symptoms and tolerance of its analgesic effects in Swiss mice by GSK-3β signaling.
Methods: This experimental study was performed on 56 Swiss male albino mice that were randomly allocated into 8 groups (each containing 7 mice). The intraperitoneal injection of morphine at different concentrations (50, 50 and 75 mg/kg) and different hours (08:00, 11:00 and 16:00, respectively) was performed for 4 days, and a single dose 50 mg/kg was administered on the 5th day. The effects of three doses of lithium (1, 5 and 10 mg/kg) given orally, 45 min before morphine injections on morphine-induced analgesic tolerance were evaluated. To evaluate analgesia latency on day 1, 3 and 5, tail flick and hot plate tests were done. The brain of each animal was removed to measure nitrite levels, and histological evaluation and immunohistochemistry for p-glycogen synthase (p-GSSer640) were performed on the last day of the study.
Results: Co-administration of lithium significantly increased the latency of analgesia in comparison with the morphine group on the 3rd and 5th day (P<0.05). Lithium reduced the morphine-induced increase of nitrite levels and also reduced brain damage. In addition, immunohistochemistry assay of p-GSSer640 indicated a significant reduction of the morphine-induced phosphorylation of GS at S640 by GSK in the lithium-treated mice.
Conclusion: Lithium administration can reduce morphine tolerance in adult male Swiss mice.